Investors

Recent Releases

February 12, 2026

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Approval will broaden the NARCAN ® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced that the U.S.

February 12, 2026

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025.

January 15, 2026

Emergent Announces Resolution of New York Attorney General Investigation

Emergent BioSolutions has reached an agreement with the Office of the Attorney General of the State of New York (OAG) to resolve its investigation related to legacy claims regarding the company’s approval of an executive trading plan in November 2020.